
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is poised for growth as a leader in blood-based organ transplant testing, with a strong market presence and ongoing innovations. The company's recent acquisition and launch of AlloHeme, targeting a significant TAM, indicate a strategic expansion beyond transplant testing. While potential risks include regulatory and operational challenges and competition, the company's financial performance and product advancements suggest a positive outlook for future success.
Bears say
CareDx is a precision medicine company that offers testing services, products, and digital solutions for transplant patients. While the company has provided LT financial targets, its success will rely on its ability to commercialize additional diagnostic solutions, which may take years to develop and gain acceptance. Additionally, potential LCD impacts and uncertain long-term plans also raise concerns about the company's future growth and profitability.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares